I&#x27;m a bit surprised by your reaction.  You do know we use genomics in clinical labs all the time, right?  We can find drug-targetable mutations in tumors, we can direct patient care in rare (and some common-ish) diseases from germline mutations.  Now, with liquid biopsy we can actually track tumor progress through treatment and identify resistance mutations that pop up.  Before long, we&#x27;ll be able to do cancer screenings from blood!  None of that would be possible without cheap, scalable NGS sequencing tech.<p>Tumor sequencing is a HUGE boon to cancer treatment and research.  Patients lives have been drastically improved by targeted treatment.